Kura Oncology, Inc.

Roger Paul Bakale

Patricia Andres

Xiaohu Deng

Dipanjan Sengupta

Yun Shan

Song Chen

Yue Lu

Craig Michael Bowe

Xiufeng Sun

Kenneth K Liu

Licheng Song

Ana Rita Neves

Catalina Ferrer

The present disclosure relates to solid forms of Compound 1, or a pharmaceutically acceptable form thereof, a pharmaceutically acceptable salt of Compound 1, or pharmaceutically acceptable solvate thereof, pharmaceutical compositions comprising the same, methods of preparing the same, and methods of treating cancer dependent on a farnesylated protein, using the same.

Solid forms of macrocyclic compounds, salts and formulations thereof, and methods of preparing and using the same

Described herein are crystalline forms of (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile or solvate thereof.

Crystalline forms of a menin inhibitor

Growing community of inventors

San Diego, CA, United States of America

Roger Paul Bakale